Genprex, Inc. (GNPX) |
| 2.01 -0.21 (-9.46%) 02-25 16:00 |
| Open: | 2.15 |
| High: | 2.2 |
| Low: | 1.92 |
| Volume: | 1,473,348 |
| Market Cap: | 3(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 3.11 |
| Resistance 1: | 2.59 |
| Pivot price: | 2.05 |
| Support 1: | 1.75 |
| Support 2: | 1.46 |
| 52w High: | 55 |
| 52w Low: | 1.71 |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Financials
| EPS | -16330000.000 |
| Book Value | 261.620 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -273.3 |
| Return on Equity (ttm) | -1.0 |
Company news
Wed, 25 Feb 2026
Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying - Benzinga
Mon, 23 Feb 2026
Genprex (GNPX) Gains Global Patent Approvals for Innovative Canc - GuruFocus
Mon, 23 Feb 2026
Genprex secures Japan, EU patents for REQORSA combos, bolstering Acclaim-3 IP and trial - TradingView
Mon, 23 Feb 2026
Japan, EU patents shield gene therapy combo for small cell lung cancer - Stock Titan
Tue, 10 Feb 2026
New Australian patent move backs gene therapy in lung cancer trial - Stock Titan
Thu, 15 Jan 2026
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
